Patient with severe burns treated using stem cell therapy – Business Standard

IANS | Mumbai June 23, 2017 Last Updated at 00:16 IST

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

Read more:

Patient with severe burns treated using stem cell therapy - Business Standard

Stem cell therapy relying on patient’s own unhealthy heart may be dangerous – Genetic Literacy Project

A new study at Tel Aviv University shows that stem cell therapy, one of the few treatments available to patients with severe and end-stage heart failure, can actually harm them unless it is done differently.

We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient, said lead researcher Jonathan Leor of the universitys Sackler Faculty of Medicine and Sheba Medical Center.

Doctors use tissue or adult stem cells to replace damaged tissue, which encourages regeneration of blood vessel cells and new heart muscle tissue. But cardiac stem cells from a diseased heart can lead to a toxic interaction via a molecular pathway between the heart and the immune system, the study found.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, Leor said. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

[Read the fully study here (behind paywall)]

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Study says some stem cells dangerous for heart patients

Read more:

Stem cell therapy relying on patient's own unhealthy heart may be dangerous - Genetic Literacy Project

ALS Research Forum | To Evaluate Stem Cell Therapies, Think … – ALS Research Forum

Testing stem cell therapies unilaterally?A side-by-side comparison of strength of key muscles may enable scientists to evaluate stem cell therapies for the disease. The approach aims to control for the variability of the disease internally, without historical cohorts and/or the use of a placebo (see Donofrio and Bedlack, 2011; Glass et al., 2016).The biceps and triceps appear to be most reliable muscles to monitor progression in people with ALS according to this analysis (Rushton et al., 2017). [Neural progenitor cells. Courtesy of Nature Cell Biology. Reproduced with permission.]

Motor neurons degenerate in ALS. Why these cells are destroyed remains unclear. Therefore, how to slow or stop this destruction of motor neurons in ALS remains an open question.

In the meantime, a growing number of scientists are turning to stem cells in hopes to promote motor neuron survival in people with ALS and/or reduce their toxicity (see December 2015 conference news). But how to evaluate these strategies in the clinic remains hotly debated.

Now, a research team at Cedar Sinai Medical Center in Los Angeles, California reports that an emerging outcome measure, which involves monitoring muscle strength, may facilitate the evaluation of stem cell therapies for the disease (Rushton et al., 2017). The study, led by Clive Svendsen, found that functional decline of key muscles on the left and right side of people with ALS progressed at a similar rate. The results suggest that at least some stem cell therapies could be evaluated unilaterally by comparing the strength of muscles on the treated and untreated side for each of these muscle groups.

This side-by-side comparison, according to a subsequent power analysis, may enable clinicians to evaluate stem cell therapies for ALS in a smaller sample size without the need for sham surgeries and/or placebo injections.

This unilateral approach is emerging as an alternative to evaluate a growing number of potential neuroprotective strategies for neurodegenerative diseases including ALS (see NCT02943850, NCT02478450; Glass et al., 2016).

The study is published on June 9 in Neurology.

The retrospective analysis, performed in collaboration with Cedar Sinais Robert Baloh, studied the rates of decline of 6 upper and lower muscle groups in nearly 750 people with ALS determined by fixed dynamometry. These longitudinal datasets, previously collected by physical therapist Pat Andres and colleagues, now at Massachusetts General Hospital, capture the decline in strength of key muscles in people with ALS during at least a 16-month period measured by either the TUFTS Quantitative Neuromuscular Exam (TQNE) or more recently, the Accurate Test of Limb Isometric Strength (ATLIS) system (Andres et al., 1986; Shields et al., 1998; Andres et al., 2012.

Analyzing therapies by hand. Meanwhile, Biogen scientists in Cambridge, Massachusetts are turning to hand-held dynamometry to evaluate potential therapies for ALS. The emerging strength-based measure highly correlates with the progressive loss of motor function (ALS-FRS-R) and breathing capacity (FVC) according to a retrospective analysis of 924 people with ALS presented at the 2017 meeting of the American Academy of Neurology (see May 2017 news). And, according to a subsequent side-by-side comparison, these musclesdecline at similar rates. [Image: Douma et al., 2014 under CC BY 2.0 license.]

The study builds on previous work, led by Barrow Institutes Jeremy Shefner in Phoenix, Arizona and Biogens Toby Ferguson in Cambridge, Massachusetts, which found that monitoring the strength of key muscles using hand-held dynamometry is a reliable and reproducible approach to measure progression of ALS in a clinical setting and thereby, may facilitate the evaluation of potential therapies (see May 2017 conference news; Shefner et al., 2014).

Now, Svendsens team is gearing up to evaluate their potential stem cell therapy for ALS. The strategy uses genetically engineered neural progenitor cells (NPCs) to deliver GDNF into the CNS in hopes to protect motor neurons in people with the disease (see April 2017 news; Gowing et al., 2014). The approach is at the phase 1 stage. Stay tuned.

Featured Paper

RushtonDJ, Andres PL, Allred P, Baloh RH,SvendsenCN. Patients with ALS show highly correlated progression rates in left and right limb muscles. Neurology. 2017 Jun 9. [PubMed].

References

ShefnerJM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M.Quantitativestrengthtesting in ALS clinical trials. Neurology. 2016 Aug 9;87(6):617-24. [PubMed].

Andres PL, Skerry LM, Munsat TL, Thornell BJ, Szymonifka J, Schoenfeld DA, Cudkowicz ME. Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2012 Jan;45(1):81-5. [PubMed].

Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL.Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology. 1986 Jul;36(7):937-41.[PubMed].

Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, Bordeau J, Fournier C, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges LF, Rutkove SB, Duell J, Patil PG, Goutman SA, Feldman EL. Transplantation of spinal cord-derived neural stem cells forALS: Analysis of phase 1 and 2 trials. Neurology. 2016 Jul 26;87(4):392-400.[PubMed].

Gowing G, Shelley B, Staggenborg K, Hurley A, Avalos P, Victoroff J, Latter J, Garcia L, Svendsen CN. Glial cell line-derived neurotrophic factor-secreting human neural progenitors show long-term survival, maturation into astrocytes, and no tumor formation following transplantation into the spinal cord of immunocompromised rats. Neuroreport.2014 Apr 16;25(6):367-72. [PubMed].

Further Reading

Atassi N, Beghi E, Blanquer M, Boulis NM, Cantello R, Caponnetto C, Chi A, Dunnett SB, Feldman EL, Vescovi A1, Mazzini L; attendees of the International Workshop on Progress in Stem Cells Research for ALS/MND. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials? Cytotherapy.2016 Dec;18(12):1471-1475. [PubMed].

Donofrio PD, Bedlack R. Historical controls in ALS trials: a high seas rescue? Neurology. 2011 Sep 6;77(10):936-7. [PubMed].

clinical trial clinical trial design disease-als gdnf neuralstem neuroprotection stem cell topic-clinical topic-randd

See more here:

ALS Research Forum | To Evaluate Stem Cell Therapies, Think ... - ALS Research Forum

Israeli Scientists: Stem Cell Therapy Not Good for All Heart Patients – The Jewish Press – JewishPress.com

Photo Credit: Nati Shohat / Flash 90

Patients with severe and end-stage heart failure have few treatment options available to them apart from transplants and miraculous stem cell therapy. But a new Tel Aviv University study has found that stem cell therapy may in fact harm patients with heart disease.

The research, led by Prof. Jonathan Leor of TAUs Sackler Faculty of Medicine and Sheba Medical Center and conducted by TAUs Dr. Nili Naftali-Shani, explores the current practice of using cells from the host patient to repair tissue and contends that this can prove deleterious or toxic for patients. The study was recently published in the journal Circulation.

We found that, contrary to popular belief, tissue stem cells derived from sick hearts do not contribute to heart healing after injury, said Prof. Leor. Furthermore, we found that these cells are affected by the inflammatory environment and develop inflammatory properties. The affected stem cells may even exacerbate damage to the already diseased heart muscle.

Tissue or adult stem cells blank cells that can act as a repair kit for the body by replacing damaged tissue encourage the regeneration of blood vessel cells and new heart muscle tissue. Faced with a worse survival rate than many cancers, a number of patients with heart failure have turned to stem cell therapy as a last resort.

But our findings suggest that stem cells, like any drug, can have adverse effects, said Prof. Leor. We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient.

Hope for improved cardiac stem cell therapy

In addition, the researchers also discovered the molecular pathway involved in the negative interaction between stem cells and the immune system as they isolated stem cells in mouse models of heart disease. After exploring the molecular pathway in mice, the researchers focused on cardiac stem cells in patients with heart disease.

The results could help improve the use of autologous stem cells those drawn from the patients themselves in cardiac therapy, Prof. Leor said.

We showed that the deletion of the gene responsible for this pathway can restore the original therapeutic function of the cells, said Prof. Leor. Our findings determine the potential negative effects of inflammation on stem cell function as theyre currently used. The use of autologous stem cells from patients with heart disease should be modified. Only stem cells from healthy donors or genetically engineered cells should be used in treating cardiac conditions.

The researchers are currently testing a gene editing technique (CRISPER) to inhibit the gene responsible for the negative inflammatory properties of the cardiac stem cells of heart disease patients. We hope our engineered stem cells will be resistant to the negative effects of the immune system, said Prof. Leor.

Meanwhile, for those unable to profit from stem cell therapy, researchers at Ben Gurion University of the Negev (BGU) have developed a revolutionary new drug that may reverse the damage and repair the diseased heart.

The newly developed drug is a polymer which reduces the inflammation in cardiovascular tissue and stops plaque build-up in arteries. Then it goes one step further and removes existing plaque in the heart, leaving healthy tissue behind.

Professor Ayelet David, a researcher at BGU revealed the drug might also help people suffering from diabetes, hypertension and other conditions associated with old age.

See original here:

Israeli Scientists: Stem Cell Therapy Not Good for All Heart Patients - The Jewish Press - JewishPress.com

On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics – STAT

TV documentary on pain treatment funded by doctor with

TV documentary on pain treatment funded by doctor with industry ties

For some chronic pain patients, without opioids, life would

For some chronic pain patients, without opioids, life would be torture

Googles bold bid to transform medicine hits turbulence under

Googles bold bid to transform medicine hits turbulence under a divisive CEO

At first meeting of Trumps opioid commission, health advocates

At first meeting of Trumps opioid commission, health advocates plead for Medicaid spending

This bill would reinstate a controversial drug discount for

This bill would reinstate a controversial drug discount for some hospitals

Up and down the ladder: The latest comings and

Up and down the ladder: The latest comings and goings

Read the original post:

On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics - STAT

Texas has sanctioned unapproved stem cell therapies. Will it change anything? – Science Magazine

Texas Governor Greg Abbott just signed a law making it easier for unproven stem cell therapies to be given to patients in his state.

Marjorie Kamys Cotera/Bob Daemmrich Photography/Alamy Stock Photo

By Kelly ServickJun. 15, 2017 , 11:15 AM

Texas Governor Greg Abbott yesterday signed a bill allowing clinics and companies in the state to offer people unproven stem cell interventions without the testing and approval required under federal law. Like the right to try laws that have sprung up in more than 30 states, the measure is meant to give desperately ill patients access to experimental treatments without oversight from the U.S. Food and Drug Administration (FDA).

In a state where unproven stem cell therapies are already offered widely with little legal backlash, bioethicists and patient advocates wonder whether the states official blessing will maintain the status quo, tighten certain protections for patients, or simply embolden clinics already profiting from potentially risky therapies.

You could make the argument thatif [the new law] was vigorously enforcedits going to put some constraints in place, says Leigh Turner, a bioethicist at the University of Minnesota in Minneapolis, who last year co-authored a study documenting U.S. stem cell clinics marketing directly to consumers online, 71 of which were based in Texas. But it would really be surprising if anybody in Texas is going to wander around the state making sure that businesses are complying with these standards, he adds. Either way, Turner says theres powerful symbolic value in setting up this conflict between state law and federal law.

The law, effective 1 September, will allow people with severe chronic or terminal illness to be treated at a clinic that purports to isolate therapeutic stem cells from adult tissuesuch as a patients own fatif their doctor recommends it after considering all other options, and if its administered by a physician at a hospital or medical school with oversight from an institutional review board (IRB). It also requires that the same intervention already be tested on humans in a clinical trial. The law sanctions a much broader set of therapies than federal rules, which already exempt certain stem cell interventions from FDAs lengthy approval process, provided the cells are only minimally manipulated and perform the same function they normally have in body.

The Texas bills clinical trial and IRB requirements seem to weed out some dubious therapies, but the language is too nebulous to protect patients, says Beth Roxland, a bioethicist at New York Universitys Langone Medical Center in New York City. The bill doesnt specify that a trial be conducted in the United States or that the therapy get clearance from FDA for human testing. You could gain access to something [as long as its] being studied in a human somewhere on the planet, she says, which in the stem cell area makes it really very scary.

Awareness about the risks of unproven stem cell therapies is growing. A case report published in The New England Journal of Medicine earlier this year documented three women who lost their vision after receiving purported stem cell injections meant to treat age-related degeneration of the retina. Such risks are also the subject of a news conference today at the annual meeting of the International Society for Stem Cell Research in Boston.

Roxland is also unnerved by a provision in the Texas law that would prevent any state government entity from interfering with a patients access to treatment. Hypothetically, if a state officially gets wind of nefarious doings at a for-profit clinic the state officials are now restrained from doing anything. She notes that that language mirrors a proposal in a federal bill known as the Trickett Wendler Right to Try Act, introduced in the Senate in January, which would prevent the federal government from interfering with a terminally ill patients access to an experimental drug outside of a clinical trial, and would prevent FDA from considering those patients outcomes in its drug approval decisions. Vice President Mike Pence signaled his support for the law in February and met with the family of Trickett Wendler, who advocated for right to try laws before her death from amyotrophic lateral sclerosis in 2015.

Others also believe that the Texas laws approval might signal a coming thaw in federal regulation of stem cell clinics. The FDA obviously doesnt have the manpower to watch over these people, says David Bales, chairman of the advocacy group Texans for Cures in Austin, which pushed for more patient protections in the new bill. We really feel like theyre trying to open up the floodgates.

See the original post:

Texas has sanctioned unapproved stem cell therapies. Will it change anything? - Science Magazine

Lab-created antibody could hold the secret to making stem cell … – Phys.Org

June 15, 2017 Researchers from the A*STAR Bioprocessing Technology Institute involved in the study. Credit: A*STAR Bioprocessing Technology Institute

Stem cells have paved the way for a new era in regenerative medicine, but their use is fraught with risk. Now, A*STAR scientists have developed an antibody that could make stem cell therapy safer.

Human pluripotent stem cells that can differentiate in a petri dish to become any cell needed to repair tissues and organs, hold great promise. Since the first human embryonic stem cells were isolated in 1998, scientists have edged closer to developing 'cell therapy' for humans. In early 2017, a Japanese man became the first patient to receive a retina transplant made of reprogrammed pluripotent stem cells to treat macular degeneration.

These potential rewards come with great risk. Differentiating stem cells into other cell types is an imperfect process, and any stem cells that remain in a culture of transplanted cells can form dangerous by-products, including tumors, such as teratomas.

"If stem cells become a cell therapy product there will be the question of safety," Andre Choo, from the A*STAR Bioprocessing Technology Institute, explains.

Choo and his team are working to make stem cell treatments safer by creating antibodies that 'clean up' the pluripotent stem cells which fail to differentiate.

In 2016, the researchers used a whole-cell immunization strategy to generate different antibodies by injecting mice with viable embryonic stem cells. They then isolated the antibodies and tested their ability to search and destroy pluripotent stem cells in a culture dish.

One antibody, tagged 'A1', was discovered which destroyed pluripotent stem cells in minutes but left other cells unharmed.

Choo's team then focused on how the antibody destroyed its target. The scientists discovered that A1 docks to sugar molecules that are only present on the surface of embryonic stem cells, setting off a signaling cascade that ruptures the stem cell.

"That was quite exciting because it now gives us a view of the mechanism that is responsible for the cell-killing effect," says Choo.

Understanding this mechanism could allow Choo's team to combine the A1 antibody with other treatments to clean stem cells from a mixture of differentiated cells even more effectively.

The finding could also pinpoint how best to target antibodies against sugar molecules on other unwanted cells, including cancer cells.

"We hope that in the near future regenerative medicine will have a place in the clinic," says Choo, who wants this antibody to be part of that process.

The A*STAR-affiliated researchers contributing to this research are from the Bioprocessing Technology Institute. For more information about the team's research, please visit the Stem Cell 1 group webpage.

Explore further: New tools to study the origin of embryonic stem cells

More information: Ji Yun Zheng et al. Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis, Cell Death and Differentiation (2017). DOI: 10.1038/cdd.2016.164

Researchers at Karolinska Institutet have identified cell surface markers specific for the very earliest stem cells in the human embryo. These cells are thought to possess great potential for replacing damaged tissue but ...

An International Reserach Team coordinated by Igb-Cnr has discovered a key role of vitamins and amino acids in pluripotent stem cells. The research is published in Stem Cell Reports, and may provide new insights in cancer ...

A*STAR researchers and colleagues have developed a method to isolate and expand human heart stem cells, also known as cardiac progenitor cells, which could have great potential for repairing injured heart tissue.

Adding just the right mixture of signaling moleculesproteins involved in developmentto human stem cells can coax them to resemble somites, which are groups of cells that give rise to skeletal muscles, bones, and cartilage ...

Scientists have discovered the gene essential for chemically reprogramming human amniotic stem cells into a more versatile state similar to embryonic stem cells, in research led by UCL and Heinrich Heine University.

Oxygen in the air is well known to cause damaging rust on cars through a process known as oxidation. Similarly, a research group at Lund University in Sweden, has now identified that certain cells during embryonic development ...

Scientists have developed a new technique for investigating the effects of gene deletion at later stages in the life cycle of a parasite that causes malaria in rodents, according to a new study in PLOS Pathogens. The novel ...

Scientists from Rutgers University-New Brunswick, the biotechnology company NAICONS Srl., and elsewhere have discovered a new antibiotic effective against drug-resistant bacteria: pseudouridimycin. The new antibiotic is produced ...

The drill holes left in fossil shells by hunters such as snails and slugs show marine predators have grown steadily bigger and more powerful over time but stuck to picking off small prey, rather than using their added heft ...

Almost all life on Earth is based on DNA being copied, or replicated. Now for the first time scientists have been able to watch the replication of a single DNA molecule, with some surprising findings. For one thing, there's ...

Researchers have identified properties in DNA's protective structure that could transform the way scientists think about the human genome.

James Cook University scientists have found evidence that even distantly related Australian fish species have evolved to look and act like each other, which confirms a central tenet of evolutionary theory.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the original post here:

Lab-created antibody could hold the secret to making stem cell ... - Phys.Org

New Law Opens Door for Stem Cell Therapy in Texas – Spectrum News

AUSTIN, Texas -- The legal battle to get patients access to stem cell therapy in Texas is closer to reality.

Gov. Greg Abbott signed such legislation into law this week, and itmeans some patients will be heading into uncharted medical territory.

Come Sept. 1, patients with terminal illnesses or severe chronic diseases will be allowed to access experimental stem cell treatments in Texas.

MORE |Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments

Currently, mostpatients who want stem cell therapy have to travel outside the United States to do it, and stem cell re-injections are only allowed here within a 24-hour window.

"This is going to protect patient health, and provide for the treatments to be done here locally at home," saidMike Byrom, the Chief Science Officer at Austin stem cell bankBioEden.

Byrom said the new lawwill keep patients in the country, and will provide renewed hope for those with serious ailments.

This hope resulted in anemotional fight this session.

Texas State Rep. Drew Springer, R-Gainesville, gave an impassioned speech for the legislation as the deadline to read new bills approached, urging lawmakers to keep it from dying.

"I'll be damned if we don't get the chance tonight to hear the very next bill that opens up the doors of medical science," saidSpringer, whose wife is wheelchair-bound."It might give somebody like my wife a chance to walk."

But not everyone's convinced this is the right way to go.

"We want access for patients to the best drugs, but we think they ought to go through the FDA approval process," saidTexans for Cures Chairman David Bales.

Bales was one of the few people who testified against the bill. While he supports more stem cell research,hearguesthe state should fund it, rather than letting for-profit businesses lead the way.

"You run the risk of medical fraud because a lot of these guys, a lot of these patients, are paying a lot of money, to physicians and drug manufacturers who haven't gone through the right process,"Balessaid.

Patients who will be participating in stem cell therapy procedures will give up their right to take legal action if something goes wrong.

---

Join the Discussion:

Follow Capital Tonight Texas on Facebook & Twitter

Keep the conversation going on our political blog: Capital Roundup .

Read the original here:

New Law Opens Door for Stem Cell Therapy in Texas - Spectrum News

‘Advances made in stem cell therapy in Asia far more than those made in US’ – The Hindu

'Advances made in stem cell therapy in Asia far more than those made in US'
The Hindu
Indigenously developed therapeutic modules for neuro development disorders like autism have demonstrated a higher rate of recovery and improvement among sufferers, Nandini Gokulchandran, a Mumbai-based researcher in the field of stem cell therapy ...

See the original post:

'Advances made in stem cell therapy in Asia far more than those made in US' - The Hindu

Stem Cell Therapy Offers Hope for Multiple Sclerosis Remission – Healthline

By combining an experimental stem cell treatment with a nanoparticle delivery system, researchers may eventually stop MS and other autoimmune diseases.

An innovative stem cell therapy could change how we treat multiple sclerosis (MS), but are we any closer to a cure?

The work of Dr. Su Metcalfe, founder and chief scientific officer of the biotech company LIFNano, appears to be breathing new life into that hope.

Metcalfe and her team developed a way to fight MS by using the bodys own natural mechanisms but it hasnt been tested in humans yet.

MS is an inflammatory and neurodegenerative autoimmune disease that can result in an array of neurological symptoms including fatigue, muscle spasms, speech problems, and numbness. It is caused by the immune system attacking myelin, the insulating coating that runs along the outside of nerve cells. The result is damage to the brain and central nervous system.

The disease currently affects roughly 2.5 million people worldwide. About 200 new cases are diagnosed each week in the United States.

LIFNano uses a new treatment based on LIF a stem cell protein that forms naturally in the body to signal and regulate the immune systems response to myelin.

LIF, in addition to regulating and protecting us against attack, also plays a major role in keeping the brain and spinal cord healthy, Metcalfe recently told Cambridge News.

In fact it plays a major role in tissue repair generally, turning on stem cells that are naturally occurring in the body, making it a natural regenerative medicine, but also plays a big part in repairing the brain when its been damaged, she said.

Metcalfe has spent years studying LIF, but only recently realized its potential for treatment likening it to an on/off switch for the immune system.

However, once she discovered its potential, there were almost immediate problems in its application. One of the earliest was how quickly LIF breaks down once it is administered into the body.

If you try just to inject it into a patient, it dissipates or disappears in about 20 minutes, Olivier Jarry, CEO of LIFNano, told Healthline.

That makes it unusable in a clinic. You would have to have some kind of pump and inject it continually.

A breakthrough came for Metcalfe when she took findings from her studies of LIF and applied them to nanotechnology. The treatment she is now developing relies on nanospheres derived from a well-established medical polymer known as PLGA, which is already used in materials like stitches. And because it is biodegradable, it can be left to dissolve inside the body.

Storing LIF inside these PLGA nanospheres before administering them into the bloodstream allows for a sustained dose over the course of several days.

The process differs significantly from the current drugs used to treat MS. These treatments most often fall under the category of drugs known as immunosuppressors, which inhibit the bodys overall immune system response.

LIF is theoretically much more precise than immunosuppressors, and should keep the immune system functioning against harmful infections and disease.

Were not using any drugs, said Metcalfe. Were simply switching on the bodys own systems of self-tolerance and repair. There arent any side effects because all were doing is tipping the balance. Autoimmunity happens when that balance has gone awry slightly, and we simply reset that.

The team cautions that LIF therapy is still several years away.

While some outlets have run wild with Metcalfes research, announcing that a cure for MS is right around the corner, those headlines are speculative.

Some MS advocacy groups have even made public statements calling coverage of her work premature and irresponsible.

Jarry told Healthline that LIFNano is expecting to enter FDA phase I trials in 2020. This would be the first time that it is used in human subjects. But even if the treatment proves to be safe and effective, the soonest it could be on the market is 2023, he estimated.

The main focus of LIF therapy is now on MS. But it has potential for treating other autoimmune diseases including psoriasis and lupus.

We are optimistic in the sense that we may provide a long-term remission for patients with MS, said Jarry.

Is it a cure? Wed love at some point to use the term cure, but we are very cautious.

Original post:

Stem Cell Therapy Offers Hope for Multiple Sclerosis Remission - Healthline

Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer’s and Parkinson’s diseases – South China Morning Post

Oper Technology, a Hong Kong biotechnology start-up, has pioneered what it claims is a world first in stem cell treatment that it says could potentially help millions of patients suffering from Alzheimers and Parkinsons diseases.

The business was co-founded by Hong Kong Baptist Universitys Professor Ken Yung, who specialises in neurobiology and neurological diseases in the universitys biology department.

He and his team has now developed a method of harvesting neural stem cells from the brains of live subjects using specially developed nanoparticles.

The exploration of using stem cells to repair damaged neural cells is not a new concept. Scientists in the US and elsewhere have experimented using stem cells from fat and skin, developing them into neural cells.

But Yung claims his team is the first to successfully harvest stem cells directly from the brain and re-inject the developed neural cells back into a live subject, thereby artificially regenerating any cells which have died off, due to neurological diseases from neural stem cells themselves.

Stem cells have the potential to develop into different types of cells with specialised functions.

The nanoparticles which are made of a type of iron oxide work like magnets to attract the stem cells within the brain.

Yung said these can then be developed into more specific neural cells and re-injected into the brain to replace damaged cells caused by diseases such as Alzheimers and Parkinsons, where neurons in the patients brains progressively die off with time.

He suggests the treatment could benefit almost 100 million patients around the world, who suffer from neurodegenerative diseases, including strokes.

China alone has the largest population of people with dementia, with an estimated 23.3 million now projected to suffer from the condition by 2030, according to the World Health Organisation.

Yung co-founded Oper Technology and serves as its chairman.

The company is being developed under Hong Kong Science and Technology Parks Incu-Bio programme, which provides select biotechnology start-ups with laboratory and support services, and ultimately it aims to commercialise its medical technology.

If you put the [developed] cells in a different environment from where the [stem cells are harvested], there might be [misdirected] growth in an uncontrolled environment, said Yung.

We want to use neural cells to repair neural cells, and since the stem cells and re-injected neural cells are from the same micro-environment, there will not be uncontrollable growth.

The method has proven to be very successful when tested on rats, especially in cases of Parkinsons, according to Yung, who suggested the method could eventually become an ultimate treatment for the disease.

Furthermore, the risks of this treatment are similar to what is currently on the market today, he added.

The treatment could also help to treat early-stage Alzheimers patients, slowing down or even halting the degeneration process, although Yung acknowledged that its effectiveness in treating terminal stage patients may be limited since it would be difficult to regenerate enough neural cells when patients brains have shrunk due to the condition.

While animals subjected to the treatment displayed an improvement in neural function following the re-injection, the team has yet to start on clinical trials as such cell therapy is still nascent and largely unregulated in Hong Kong.

Oper Technology is currently seeking investment and often sets up booths at conferences such as last weeks EmTech Hong Kong conference, which focuses on innovation and emerging technologies.

Yung hopes to raise enough funds to begin clinical trials in Australia in the near future, where autologous cell therapies are legal and thus provides an ideal environment for clinical trials.

Continue reading here:

Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer's and Parkinson's diseases - South China Morning Post

Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments – Spectrum News

AUSTIN, Texas -- Gov. Greg Abbott has signed a new law that allows terminally ill or those which chronic diseases receive stem cell treatments in Texas.

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, and is often patient's last hope for improvement.

Bone marrow transplant is the most widely used stem-cell therapy, and can often help those with multiple sclerosis and other diseases.

House Bill 810, which was introduced by Rep. Tan Parker, R-Flower Mound, passed in both the Texas House and Senate.

"It is easy to fall into the trap of viewing legislation as just words on a piece of paper," said Sen. Paul Bettencourt, R-Houston, the bill's sponsor in the Senate. "But for the many people who are ill with multiple sclerosis and other diseases that stem cell therapy has the hope of solving in our lifetime, I look at this bill, I look at the possibility of what can happen in the 21st Century, with Texas taking the lead on adult stem cell treatments and this bill has the potential to extend lives and make a difference for these patients."

The Texas Medical Board will be responsible for writing the rules for the treatment.

"Everyone has a zest for life. This adult stem cell treatment possibility gets government out of the way to let these new therapies flourish and give these patients hope for a future good quality of life," Bettencourt added.

The legislation takes effect Sept. 1.

-- Value of Stem Cell Therapy --

According to the National Institues of Health, stem cellshave the remarkable potential to develop into many different cell types in the body during early life and growth.

In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive.

When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Doctors say stem cells are important for living organisms for many reasons.

In the 3- to 5-day-old embryo, called ablastocyst, the inner cells give rise to the entire body of the organism, including all of the many specialized cell types and organs such as the heart, lungs, skin, sperm, eggs and other tissues.

In some adult tissues, such as bone marrow, muscle, and brain, discrete populations of adult stem cells generate replacements for cells that are lost through normal wear and tear, injury, or disease.

---

Join the Discussion:

Follow Spectrum News Austin on Facebook | Twitter | Instagram

Read this article:

Governor Signs Law to Allow Chronic, Terminally Ill in Texas to Get Stem Cell Treatments - Spectrum News

Stem Cell Therapy Becomes Law in Texas – PR Newswire (press release)

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studiesregistered with theNational Institute of Health (NIH) for these diseases."

"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. Ihad only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws like the one just passed in Texas, built on model legislation from the Goldwater Institute in Arizona, will allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."

Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

"We're on the cusp of a major change on how patients can access stem cell therapy," saidAlexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."

ABOUT StemGenex Medical Group

StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment,StemGenex sponsors five clinical outcome studiesregistered with theNational Institutes of Health (NIH) for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.

Contact: Jamie Schubert, Director of Media & Community Relations jschubert@StemGenex.com, (858) 242-4243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-becomes-law-in-texas-300472809.html

SOURCE StemGenex Medical Group

http://www.stemgenex.com

Read the original here:

Stem Cell Therapy Becomes Law in Texas - PR Newswire (press release)

Stem Cell Therapy: Repair and Regenerate Our Bodies – Live … – Live Trading News

Stem Cell Therapy: Repair and Regenerate Our Bodies

$USRM

Stem Cells 101: The primary purpose of stem cells is to maintain, heal and regenerate tissues wherever they reside in the body. This is a continuous process that occurs inside the body throughout life. If we did not have stem cells, our lifespan would be about 1 hour, because there would be nothing to replace exhausted cells or damaged tissue.

Notably: any time the body is exposed to any sort of toxin, the inflammatory process causes stem cells to swarm the area to repair the damage.

While it is easy to think of stem cell therapy as some sort of magic, it is wise to implement strategies that nourish and optimize the stem cells we already have in your body.

Dr. Kristin Comella, a notable Stem Cell innovator, writes: You have to create an appropriate environment for these cells to function in. If you are putting garbage into your body and youre constantly burdening your body with toxins, your stem cells are getting too distracted trying to fight off those toxins. By creating an appropriate environment, optimizing your diet and reducing exposure to toxins, that will allow the stem cells that were putting in to really home in and focus on the true issue that were trying to treat.

The other thing weve discovered over the years is that [stem cell therapy] is not the type of thing where you take one dose and youre cured forever. Your tissues are constantly getting damaged Youre going to have to repeat-dose and use those stem cells to your advantage.

When you think about a lizard that loses its tail, it takes two years to grow back the tail. Why would we put unrealistic expectations on the stem cells that were trying to apply to repair or replace damaged tissue? This is a very slow process. This is something that will occur over months and may require repeat dosing.

Stem cells historically were isolated from bone marrow, and have been used for bone marrow transplants for cancer patients since the 1930s. However, we can get stem cells from just about any tissue in the body, every tissue contains stem cells.

Actually our marrow has very low amounts of mesenchymal stem cells, which are now believed to be the most important, from a therapeutic perspective.

Mesenchymal stem cells help trigger an immunomodulatory response or a paracrine effect, which means they send signals out to the rest of the body, calling cells to the area to help promote healing.

What weve discovered in more recent years is that a more plentiful source of stem cells is actually your fat tissue. [Body] fat can contain up to 500 times more cells than your bone marrow, as far as these mesenchymal type stem cells go.

One thing thats also critically important when youre talking about isolating the cells is the number of other cells that are going to be part of that population. When youre isolating a bone marrow sample, this actually is very high in white blood cells, which are pro-inflammatory, Ms. Comella writes.

White blood cells are part of the human immune response.

When an injury occurs, or a foreign body enters our system, white blood cells will attack. Unfortunately, white blood cells do not discriminate, and can create quite a bit of damage as they clean the area out.

Stem cells, in particular the mesenchymal cells, quiet down the white blood cells and then start the regeneration phase, which leads to new tissue. Bone marrow tends to be very high in white blood cells and low in the mesenchymal cells.

So, isolating stem cells from fat tissue is preferred not only because its easier on the patient, but fat also contains a higher population of mesenchymal cells and fewer white blood cells.

The benefit also of isolating [stem cells from] fat is that its a relatively simple procedure. Theres typically no shortage of fat tissue, especially in Americans, Dr.. Comella says. Also, as you age, your bone marrow declines with regards to the number of cells in it, whereas the fat tissue maintains a pretty high number of stem cells, even in older individuals.

Fat can be successfully harvested from just about anyone, regardless of their age or how thin they are. The procedure is done under local anesthesia, meaning that the patient stays awake. We can harvest as few as 15 cubic centimeters of fat, which is a very small amount of fat, and still get a very high number of stem cells.

A stem cell procedure can cost anywhere from $5,000 15,000, depending on what one is having done, and rarely if ever will insurance cover it.

Still, when compared it to the cost of long-term medications or the out-of-pocket cost of getting a knee replacement, stem cell therapy may still be a less expensive alternative.

Also, a single extraction will typically yield enough stem cells for 20 to 25 future treatments, should one decide to store his/her stem cells for future needs.

I think its accessible for patients, Dr.. Comella says. Its an out-patient procedure. You plan to be in clinic for about two hours; no real limitations afterwards, just no submerging in water, no alcohol, no smoking for a week. But other than that, patients can resume their normal activities and go about their regular daily lives.

She notes that patients who eat a very healthy diet, focusing on Organic and grass fed foods, have body fat that is very hearty and almost sticky, yielding high amounts of very healthy stem cells.

We can grow much better and faster stem cells from that fat than [the fat from] somebody who eats a grain-based diet or is exposed to a lot of toxins in their diet, she says. Their fat tends to be very fluffy, buttery yellow. The cells that come out of that are not necessarily as good a quality. Its just been very interesting. And of note, patients that are cigarette smokers, their fat is actually gray-tinged in color. The stem cells do not grow well at all.

What has been described above is whats called an autologous donation, meaning a person is getting the stem cells from oneself. A number of companies provide non-autologous donations using cells harvested from other people, typically women, like amniotic or embryonic mesenchymal cells.

This is an important distinction.

There are now just a couple of studies that have been published comparing an autologous source, meaning cells from you own body, to an allogeneic source, meaning cells from someone else.

So far, what has been discovered is that the autologous cells will outperform somebody elses cells inside ones body. This is not fully understood yet. It may be that the environment that ones own cells function in, and that they used to that environment. They recognize it. It is the same DNA and they can function well there.

But, once the culture is expanded and a pure population of these mesenchymal cells, not necessarily the sample thats coming right off of the liposuction, but a sample that has been taken to the lab and grown, those cells will not elicit an immune response if you use them in someone else. You could scientifically and medically use those in an unmatched person. However, there are some regulatory aspects of that with regards to the FDA.

In the US, there are a variety of new stem cell products available, referred to as amniotic, cord blood products or placenta products, which are prepared at a tissue bank. Such facilities must be registered with the FDA, and the products must undergo additional processing.

For example, they must be morselized, or snap frozen or blended in some way. Such processing typically breaks the membrane, releasing growth factors, and the resulting products are called acellular, meaning there are no living cells remaining in the sample.

The amniotic products available in the US are not so much stem cell products as they are growth factor products.

Dr. Comella notes: They can be useful in creating an immunomodulatory response, which can help to promote healing, but that still differs from the living stem cell procedures that can be done by either isolating cells from your fat or bone marrow. As a general rule, you do not achieve the clinical benefits when using an amniotic product, primarily because they do not contain living stem cells.

I want to contrast that to what are called embryonic stem cells, Dr. Comella adds. The products obtained from cord blood, from women who are having babies, are not embryonic stem cells. Embryonic stem cells are when you are first bringing the egg and sperm together. Three days after that, you can isolate what is called an inner cell mass. This inner cell mass can be used to then grow cells in culture, or that inner cell mass could eventually lead to the formation of a baby.

Those are embryonic stem cells, and those are pluripotential, meaning that they have the ability to form an entire being, versus adult stem cells or stem cells that are present in amniotic tissue, [which] are multipotential, which only have the ability to form subsets of tissue.

When youre dealing with different diseases or damaged tissue or inflammation, mostly you want to repair tissue. If somebody has damage in their knee, they dont necessarily need embryonic cells because they dont need a baby in their knee. They need new cartilage in their knee.

A common question is whether stem cells can cause overgrowth, leading to cancer or tumor formation.

As noted by Dr. Comella, this is a problem associated with embryonic stem cells, which tend to grow very rapidly and can form a teratoma because of the rapid cell growth. Adult stem cells, the cells obtained from ones own body, have growth inhibitions and will not form teratomas.

The theoretical concern that has been addressed in animal models or in petri dishes is that if you take cancer cells that are growing in a dish and apply stem cells, it may make those cancer cells grow more rapidly. But this does not translate in-vivo to humans.

If there was truly an issue with applying stem cells to a patient who has cancer, we would know about it by now, because weve been dosing cancer patients with stem cells since the 1930s. The safety profile is strong and there are tens of thousands of patients documented with these treatments, Dr. Comella says.

Another useful therapy is platelet-rich plasma (PRP).

Our peripheral blood contains platelets, which act as 1st responders when theres an injury. They come in and start the clotting mechanism, thereby preventing one from bleeding to death. They also give marching orders to other cells.

For example: platelets can command stem cells to multiply and grow, or to differentiate and form new tissue.

These platelets also have many different growth factors associated with them, which can help to promote healing and stop inflammation. PRP involves taking a blood sample and then spinning the blood in a centrifuge to isolate the platelets. The platelet-rich plasma is then injected back into the area that is inflamed.

One of the most common uses of platelet-rich plasma or PRP is in a joint. Now, platelets are going to be most successful in something that is rich in stem cells [such as] an acute or a very recent injury.

If you just hurt your knee, the first thing you should do is get PRP, because its going to help promote healing, and those platelets will attach to the surface receptors of the stem cells that are already going to the area to promote healing. It would be like putting fertilizer on your seed, which are the stem cells.

If you have something more chronic, this tends to be a stem cell-poor environment. In other words, you have osteoarthritis or youve got knee pain thats 5 years old and its been there for a long time; just putting PRP in it would be like putting fertilizer on dirt without planting a seed first.

The beauty of stem cell therapy is that it mimics a process that is ongoing in the human body all the time. Our stem cells are continuously promoting healing, and they do not have to be manipulated in any way. The stem cells naturally know how to home in on areas of inflammation and how to repair damaged tissue.

All were doing is harnessing the cells from one location where theyre sitting dormant and relocating them to exactly where we want them and we need them to work, Dr. Comella says. Basically, anything inside your body that is inflamed, that is damaged in some way, that is lacking blood supply, the [stem] cells can successfully treat.

That means orthopedics, knee injections, shoulder injections, osteoarthritis, acute injuries, anterior cruciate ligament tears in the back, back pain associated with degenerative disc disease or damaged tendons or ligaments, herniated and bulging discs. You can also use it in systemic issues, everything from diabetes, to cardiac, to lungs, any tissue organ inside your body that has been damaged.

Autoimmune diseases can also be treated. The stem cells are naturally immunosuppressant, meaning they can help quiet down an over reactive immune system and help the immune system function in a more normal way. Neurological diseases, traumatic brain injury, amyotrophic lateral sclerosis, Parkinsons. All of these have to do with tissue thats not functioning properly. The cells can be used to address that.

It is very impressive, the list of different diseases that could benefit from this intervention.

Again, it is not magic, but one can dramatically improve the benefits of this intervention by combining it with other healthy lifestyle factors that optimize mitochondrial function, such as eating a healthy Real food diet, exercising, sleeping well, avoiding toxins and detoxifying from toxic influences.

Stem Cells for Anti-Aging: Stem cells can also be used as part of an anti-aging program.

Dr. Comella has used stem cells on herself for several years, and report feeling better now than she did 10 year ago.

She writes,The ability to reduce inflammation inside your body is basically making yourself live longer. Inflammation is what kills us all. Its what makes our telomeres shrink. Its what causes us pain and discomfort. Its what makes the tissues start to die. The ability to dose yourself with stem cells and bring down your inflammation, which is most likely caused by any sort of toxin that youve been exposed to, breathing air is exposure to toxins, this is going to lengthen your lifespan.

I typically will do a dose every six to 12 months, regardless of whats going on. If I have anything that is bothering me, if I tweak my knee at the gym, then I absolutely will come in and do an injection in my knee. I want to keep my tissue healthy for as long as possible.

I want to stay strong. I dont want to wait until something is wrong with me. I think that this is the future of medicine. This is what were going to start to see. People will begin to get their regular doses of [their own] stem cells and itll just be common practice.

Keep in mind theres a gradual and progressive decline in the quality and the number of stem cells as we age, so if considering this approach, it would be to your advantage to extract and bank your stem cells as early on as possible. US Stem Cell provides a stem cell bank service, so one can store them until a later date when you might need them.

Your stem cells are never as young as they are right now. Every minute that you live, your telomeres are shrinking. The ability to lock in the youth of your cells today can be very beneficial for you going forward, and for your health going forward. God forbid something happens. What if you have a heart attack? Youre not going to get clearance to get a mini-lipo aspirate procedure.

If you have your cells waiting in the bank, ready for you, it becomes very easy to pull a dose and do an IV delivery of cells. Its almost criminal that were not doing this for every single one of our cardiac patients. This should be standard practice. We should be having every single patient bank their stem cells at a young age and have them waiting, ready and available. The technology is there. We have it. Im not sure why this technology is not being made available to everyone, she says.

I think stem cell therapy is very different than traditional medicine. Stem cell therapy may actually make it so that you dont have to be dependent on pharmaceutical medications. You can actually repair the tissue and thats it. This is a very different way of viewing medicine.

For a Physician in your area providing the service, you can go there. US Stem Cell can help you locate a qualified doctor.

Eat healthy, Be healthy, Live lively

blood, bodies, body, cell, cells, damage, grow, help, knee, patients, regenerate, repair, stem, tissue, USRM

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Follow this link:

Stem Cell Therapy: Repair and Regenerate Our Bodies - Live ... - Live Trading News

Joslin Diabetes Center Creates Center for Cell-Based Therapy for Diabetes (CCTD) – Newswise (press release)

Newswise BOSTON, MA (June 8, 2017) Researchers and clinicians at Joslin Diabetes Center have established a Center for Cell-Based Therapy for Diabetes (CCTD), the goal of which is to lead the development and translation of cell-based interventions to treat and cure diabetes and its complications. This opportunity has been created by recent groundbreaking discoveries in converting stem cells into functional insulin-producing beta cells, the identification of new growth factors that stimulate beta cell regeneration, novel insights on improving treatments of diabetic complications, and evolving technologies for detection, modulation and protection against the immune responses.

A major part of CCTD, led by its interim director Dr. Gordon Weir, is the participation and coordination of program activities with the Boston Autologous Islet Replacement Therapy (BAIRT) program. This large consortium consists of Joslin, the Harvard Stem Cell Institute, Brigham and Womens Hospital (BWH), Dana-Farber Cancer Institute, and Semma Therapeutics. BAIRT aims to perform autologous stem cell derivation to clinical-grade beta cells that can provide personalized therapy for people with diabetes. The program is expected to provide the clinical proof of principle that such a stem cell therapy will be safe and effective in regulating blood sugar levels. We hope the collaboration of these leading Boston institutions with Joslin will soon result in the first demonstration of using patients own cells to correct diabetes, said Dr. Weir.

Complementing this work are recent advances at Joslin identifying new islet growth in patients with long-standing type 1 diabetes, as well as identifying potential islet growth factors, which occur in situations of insulin resistance, that could be used to stimulate the growth of the patients own beta cells. Additional early stage research is also ripe for further development at CCTD.

Findings from Dr. George Kings laboratory at Joslin point to novel pathways to treat skin fibroblasts from diabetes patients to improve wound healing. Discussions with collaborating partners at BWH and Beth Israel Deaconess Hospital are underway to translate the findings into viable therapeutic approaches. CCTD is also planning stem cell-based research for diabetic eye disease, for which a variety of stem cell-based therapies have been evaluated in clinical trials. There have been substantial advances made in stem cell research and regenerative medicine, said Dr. King, Chief Scientific Officer at Joslin. We would like to harness the potential of cell therapy to treat and reverse diabetes and its complications.

Regardless of the targeted organ for cell replacement or regeneration, the shared challenges in cell therapies for diabetes such as transplant procedure and immune rejection will be well- served by the collective expertise within CCTD. Other researchers at Joslin are conducting large scale genetic screening for novel therapeutic targets to control autoimmunity, which will complement the effort of BAIRT to extend autologous beta cell replacement to patients with type 1 diabetes.

Joslin has a long history of providing cutting-edge diabetes clinical care and research, said Dr. Peter Amenta, President and CEO of Joslin Diabetes Center. With the addition of the CCTD, Joslin will continue to accelerate the rate of diabetes research and its ability to benefit patients as early as possible.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S. For more information, visit http://www.joslin.org.

Read the original post:

Joslin Diabetes Center Creates Center for Cell-Based Therapy for Diabetes (CCTD) - Newswise (press release)

Texas is leading the charge on stem cell therapy – ThinkProgress

In the last weeks of the legislative session, Texas lawmakers passed a historic bill that legalizes investigative stem cell treatments for chronically ill patients. Despite the prevalence of unregulated stem cell clinics in the United States, this could be the first time a state has authorized the treatment for chronic illnesses, if the states governor approves the legislation.

Youre watching an episode of In Session, a weekly series exploring interesting policy changes on the state level.

PHOEBE GAVIN, ThinkProgress: Youll never guess which state is on track to become the first to recognize stem cell therapy as a treatment for chronic illnesses. Ill give you a hint: its former governor and our former president once banned federal funding for research on embryonic stem cells

You guessed it: Its The Lone Star State!

In the last week of its legislative session, Texas lawmakers approved a bill that legalizes Investigational Stem Cell Treatment, which basically means treatments that have been evaluated by an institutional review board but have not yet been approved by the FDA.

Keep in mind, though: this isnt about embryonic stem cells. The cells will come from banked umbilical cords and the patients themselves, who will be allowed to pursue the treatment as a last resort. So people who suffer from debilitating chronic illnesses like Parkinsons, ALS, and multiple sclerosis could see relief.

For TX Rep. Springer, this is personal.

REP. DREW SPRINGER (R-TX68): I pray to God every time I go to mass, every time I close my eyes, that one day my wifeand not for my sake, but for her sakewould have the chance to have that opportunity again to be able to walk.

GAVIN: The bill almost missed the deadline until he came to the podium. After his plea, it unanimously passed the House and sailed through the Senate. It now awaits Gov. Greg Abbotts signature, and hes already tweeted his support for it.

But not everyone is on board. Two different stem-cell research organizations have vocalized their opposition, arguing that the lack of quote rigorous evidence of safety and efficacy would put vulnerable patients at risk.

But the reality is, patients have already been taking this risk without the states explicit authorization. There are hundreds of clinics across the country that have been operating under regulatory loopholesat least 71 in TX alone. Without regulation, these clinics are completely unchecked. And patients who seek help there have felt the consequences: theyve been blinded, developed tumors and even died after seeking unregulated stem cell treatment. But with this new bill, if something goes wrong, patients have the right to sue.

So there you goTexas, creating accountability for stem cell clinics for the first time in the US. An unprecedented act from a unpredictable state.

Go here to see the original:

Texas is leading the charge on stem cell therapy - ThinkProgress

Abused pup receives cutting-edge stem cell therapy – fox5sandiego.com


fox5sandiego.com
Abused pup receives cutting-edge stem cell therapy
fox5sandiego.com
SAN DIEGO Abused orphan pup "Dwyane," who has severe disfigurements, is on the road to recovery after stem cell therapy by a Poway-based company. The one-year-old puppy was reportedly kicked, beaten and forced to wear a wire muzzle before he ...
Severely abused dog receives stem cell therapy - CBS News 8 - San Diego, CA News Station - KFMB Channel 8CBS 8 San Diego

all 2 news articles »

View original post here:

Abused pup receives cutting-edge stem cell therapy - fox5sandiego.com

Stem cell therapy will attempt to bring the dead back to life – New York Post


New York Post
Stem cell therapy will attempt to bring the dead back to life
New York Post
Attempts to bring people back from the dead could start in a few months, it's been reported. Bioquark, a Philadelphia-based company, has revealed it will start new stem cell therapy trials in an unidentified country in Latin America later this year.

More:

Stem cell therapy will attempt to bring the dead back to life - New York Post

Scientists set to trial new stem cell therapy to ‘reawaken’ the brain … – The Sun

A US company has revealed it will start tests in an unidentified country in Latin America later this year

ATTEMPTS to bring people back from the dead could start in a few months, its been reported.

A US company has revealed it will start new stem cell therapy trials in an unidentified country in Latin America later this year.

Getty Images

In the majority of countries, to be officially declared dead requires an complete and irreversible loss of brain function.

But Bioquark says it has developed a series of injections that can reboot the brain and bring people back to life, according to MailOnline.

CEO Ira Pastor revealed the firm will begin testing itsmethod on humans and have no plans to try it out on animals first.

Pastor and orthopaedic surgeon Himanshu Bansal initially hoped to carry out tests in India last year.

Butthe Indian Council of Medical Research pulled the plug on their plans and asked them to to take the trials elsewhere.

In details published on a clinical trials database, scientists plan to examine individuals aged between 15 and 65 who have been declared brain dead from a traumatic brain injury.

They intend to use MRI scans to look for possible signs of brain death reversal before carrying out the trial, which will happen in three stages.

The first step involves harvesting stem cells from the patients own blood before injecting them back into their body.

Then the patient would be given a dose of peptides injected into their spinal cord.

Getty Images

Lastly they would undergo a 15-day course of laser and median nerve stimulation while monitoring the patient with MRI scans.

Consent is likely to be an issue for the researchers as technically all of the patients will be brain dead.

However the study detail states that it can accept written informed consent from the legally acceptable representative of the patient.

The Bioquark trials are part of a broader project called ReAnima, of which Pastor is on the advisory board.

The project explores the potential of cutting edge biomedical technology for human neuro-regeneration and neuro-reanimation.

Speaking to MailOnline last year, Pastor said: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

We pay for your stories! Do you have a story for The Sun Online news team? Email us at tips@the-sun.co.uk or call 0207 782 4368

Read more here:

Scientists set to trial new stem cell therapy to 'reawaken' the brain ... - The Sun

Doctors Targets Stem Cell Therapy Launch – Bahamas Tribune

ByNEIL HARTNELL

Tribune Business Editor

nhartnell@tribunemedia.net

DOCTORS Hospital plans to launch stem cell therapy and enter the primary healthcare market during its current financial year, after profits for the year to end-January 2017 increased five-fold.

The BISX-listed healthcare provider said it planned to launch both initiatives at its Bahamas Medical Centre facility on Blake Road, having received the necessary approvals for one stem cell programme and another in its final stages.

Doctors Hospitals 2017 annual report did not identify the types of stem cell treatment involved, but said: It is envisioned that stem cell therapy will occur at the facility [Bahamas Medical Centre] in fiscal 2018, with one programme already receiving the necessary approvals and the second programme in its final stages of assessment and approval......

We anticipate that in fiscal 2018 we will launch one of our primary care centres at this location, supported by increased specialist services to best serve the neighbouring communities.

Joe Krukowski, Doctors Hospitals chairman, told shareholders via the annual report that the launch of primary care services will be a vital component in the continuum of care we provide.

We will seek to provide our customers with multiple entry points for this level of care, he added.

Doctors Hospitals stem cell initiatives, in particular, represent a potential boost to the Bahamas national effort to make greater inroads into the medical tourism market while also exploiting legislation passed by the former Christie administration.

The healthcare providers move into primary care will effectively create a fully-integrated model, combining with its core business in secondary and tertiary care provision to potentially make Doctors Hospital almost a one-stop shop for all medical needs.

The expansion comes after Doctors Hospital saw total comprehensive income for the year to end-January 2017 grow by 409 per cent or more than five-fold, from $702,790 to $3.578 million year-over-year.

The growth was driven entirely by the companys main Collins Avenue facility, where profits more than doubled, increasing by 157.4 per cent to $4.778 million compared to $1.856 million the year before. The Bahamas Medical Centres net loss increased slightly compared to the prior year, rising from $1.153 million to $1.2 million.

An improved top-line drove Doctors Hospitals improved profitability, with patient services revenue up $3.65 million or 7.4 per cent at $52.713 million.

Patient days increased by 6 per cent from the previous year, the annual report said of the main Collins Avenue hospital. Increases in the Intensive and Intermediary Care Units accounted for 37per centof the change, and the balance in medical surgical and maternity.

Total admissions to the facility were 4,114 in fiscal 2017 compared to 4,063 in fiscal 2016. The continued flat admission numbers and increased patient days are indicative of the trend toward a rising severity of illness. The average daily census increased to 33 patients per day from 31.2 in the previous year.

Doctors Hospitals total expenses grew by $818,452 or 1.7 per cent year-over-year, with salaries and benefits rising by $1.176 million or 5.6 per cent to $23.209 million. Due to the top-line growth, these fell as a percentage of patient net revenue from 44.3 per cent to 43.5 per cent.

At Bahamas Medical Centre, revenues rose by $28,015 or 1.9 per cent to $1.462 million. This slightly outpaced the increase in expenses, which jumped by 1.5 per cent or $43,479 to $2.819 million as a result of rising medical supplies costs.

Doctors Hospital is budgeting $7 million for capital spending projects in its financial year to end-January 2018, a sum more than double the prior years $3.1 million, as it bids to upgrade facilities and replace equipment.

Bad debt expense, as a percentage of patient service revenues, decreased to 2.6per centfor the year ended January 31, 2017, compared to 3.4per centthe previous year, Doctors Hospital said.This represented a decrease of $316,808, or 18.8per cent. This decrease is a result of a write-off of third-party receivables.

The number of days revenue in accounts receivable at year-end (AR Days) for fiscal 2017 stand at 51 compared with fiscal 2016 at 43 days, and net receivables as a percentage of net patient revenue increased to 14.1per centfrom 11.8per cent. These increases area result of high activity in the months of December and January, and payments not received until after year-end.

Excerpt from:

Doctors Targets Stem Cell Therapy Launch - Bahamas Tribune